1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Regado Biosciences, Inc. - Product Pipeline Review - 2014

Regado Biosciences, Inc. - Product Pipeline Review - 2014

  • October 2014
  • -
  • Global Markets Direct
  • -
  • 24 pages

Regado Biosciences, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Regado Biosciences, Inc. - Product Pipeline Review - 2014’, provides an overview of the Regado Biosciences, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Regado Biosciences, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Regado Biosciences, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Regado Biosciences, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Regado Biosciences, Inc.’s pipeline products

Reasons to buy

- Evaluate Regado Biosciences, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Regado Biosciences, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Regado Biosciences, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Regado Biosciences, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Regado Biosciences, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Regado Biosciences, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Regado Biosciences, Inc. - Product Pipeline Review - 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Regado Biosciences, Inc. Snapshot 4
Regado Biosciences, Inc. Overview 4
Key Information 4
Key Facts 4
Regado Biosciences, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Regado Biosciences, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Regado Biosciences, Inc. - Pipeline Products Glance 9
Regado Biosciences, Inc. - Clinical Stage Pipeline Products 9
Phase I Products/Combination Treatment Modalities 9
Regado Biosciences, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
Regado Biosciences, Inc. - Drug Profiles 12
REG-2 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
REG-3 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Aptamers for Cardiovascular Diseases 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Regado Biosciences, Inc. - Pipeline Analysis 16
Regado Biosciences, Inc. - Pipeline Products by Target 16
Regado Biosciences, Inc. - Pipeline Products by Route of Administration 17
Regado Biosciences, Inc. - Pipeline Products by Molecule Type 18
Regado Biosciences, Inc. - Pipeline Products by Mechanism of Action 19
Regado Biosciences, Inc. - Recent Pipeline Updates 20
Regado Biosciences, Inc. - Discontinued Pipeline Products 21
Discontinued Pipeline Product Profiles 21
REG-1 21
Regado Biosciences, Inc. - Locations And Subsidiaries 22
Head Office 22
Other Locations and Subsidiaries 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 24
Disclaimer 24

List of Tables
Regado Biosciences, Inc., Key Information 4
Regado Biosciences, Inc., Key Facts 4
Regado Biosciences, Inc. - Pipeline by Indication, 2014 6
Regado Biosciences, Inc. - Pipeline by Stage of Development, 2014 7
Regado Biosciences, Inc. - Monotherapy Products in Pipeline, 2014 8
Regado Biosciences, Inc. - Phase I, 2014 9
Regado Biosciences, Inc. - Preclinical, 2014 10
Regado Biosciences, Inc. - Discovery, 2014 11
Regado Biosciences, Inc. - Pipeline by Target, 2014 16
Regado Biosciences, Inc. - Pipeline by Route of Administration, 2014 17
Regado Biosciences, Inc. - Pipeline by Molecule Type, 2014 18
Regado Biosciences, Inc. - Pipeline Products by Mechanism of Action, 2014 19
Regado Biosciences, Inc. - Recent Pipeline Updates, 2014 20
Regado Biosciences, Inc. - Discontinued Pipeline Products, 2014 21
Regado Biosciences, Inc., Other Locations 22

List of Figures
Regado Biosciences, Inc. - Pipeline by Top 10 Indication, 2014 6
Regado Biosciences, Inc. - Pipeline by Stage of Development, 2014 7
Regado Biosciences, Inc. - Monotherapy Products in Pipeline, 2014 8
Regado Biosciences, Inc. - Pipeline by Top 10 Target, 2014 16
Regado Biosciences, Inc. - Pipeline by Top 10 Route of Administration, 2014 17
Regado Biosciences, Inc. - Pipeline by Top 10 Molecule Type, 2014 18
Regado Biosciences, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.